Modified chimeric polypeptides with improved pharmacokinetic properties
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsNicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
Life of this patent
Estimating the term…
Abstract
The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.
Claims13
1-14. (canceled)
A chimeric polypeptide capable of antagonizing VEGF activity consisting of a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component,
- wherein the modified extracellular ligand binding domain consists of an immunoglobulin-like (Ig) domain of human Flt1 and an Ig domain of human Flk1, wherein the Ig domain of human Flt1 is Ig domain 2, and wherein the Ig domain of human Flk1 is Ig domain 3,
- wherein the chimeric polypeptide exhibits improved pharmacokinetic properties as compared to a chimeric polypeptide consisting of only Ig domains of Flt1.
A chimeric polypeptide capable of antagonizing VEGF activity consisting of a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component,
- wherein the modified extracellular ligand binding domain consists of one or two immunoglobulin-like (Ig) domains of human Flt1 and one or two Ig domains of human Flk1, wherein at least one of the Ig domains of human Flt1 is Ig domain 2, and wherein at least one of the Ig domains of human Flk1 is Ig domain 3, wherein the chimeric polypeptide exhibits improved pharmacokinetic properties as compared to a chimeric polypeptide consisting of only Ig domains of Flt1.
Dependencies are inferred from the claim text.